top of page
Kim Tsui 4.jpg

Post Doctoral Fellow


I received my bachelor’s degree in Molecular, Cell, and Developmental Biology at UCLA, where I studied axon targeting in the laboratory of Lawrence Zipursky. For my PhD, I worked in Michael Bassik’s lab at Stanford University to study how an emerging class of targeted cancer therapeutics, Antibody-drug conjugates (ADCs), are internalized and activated specifically in cancer cells. Using genome-wide CRISPR screens, I identified many novel genetic regulators of ADC toxicity. I also uncovered surprising links between cell surface glycosylation and ADC efficacy.

In the Dillin lab, I am interested in how ER stress alters glycosylation of cell surface and secreted proteins. My goal is to understand how these changes in glycosylation impact protein function and influence cell-cell communication.


Tsui, C.K., Barfield, R.M., Fischer, C.R., Morgens, D.W., Li, A., Smith, B.A.H., Gray, M.A., Bertozzi, C.R., Rabuka, D., and Bassik, M.C. (2019). CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat. Chem. Biol. 15, 949–958.


Pegram, M.D., Miles, D., Tsui, C.K., and Zong, Y. (2019). HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin. Cancer Res. clincanres.1976.2019.


Haney, M.S., Bohlen, C.J., Morgens, D.W., Ousey, J.A., Barkal, A.A., Tsui, C.K., Ego, B.K., Levin, R., Kamber, R.A., Collins, H., et al. (2018). Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat. Genet. 50, 1716–1727.


Morgens, D.W., Wainberg, M., Boyle, E.A., Ursu, O., Araya, C.L., Tsui, C.K., Haney, M.S., Hess, G.T., Han, K., Jeng, E.E., et al. (2017). Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 15178.

Kim Tsui, Ph.D. TeamMember
bottom of page